2018


Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
2018/№2

Ивабрадин в современной фармакотерапии сердечно- сосудистых заболеваний – реалии и перспективы

Голосова А. Н., Гацура С. В., Ульянова Е. А., Карамышева Е. И., Дворянчикова Ж. Ю.
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А. И. Евдокимова» Минздрава РФ, Москва

Ключевые слова: ивабрадин, ритмурежающая терапия, ишемическая болезнь сердца, артериальная гипертония, микроциркуляция

DOI: 10.18087/cardio.2018.2.10088

  1. Gislason G. H., Rasmussen J. N., Abildstrоm S. Z. et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153–1158.
  2. Postea O., Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discov 2011;10:903–914.
  3. Ragueneau I., Laveille C., Jochemsen R. et al. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998;64:192–203.
  4. Colin P., Ghaleh B., Monnet X. et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003;284 (2):676–682.
  5. Simon L., Ghaleh B., Puybasset L. et al. Coronary and haemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995;275:659–666.
  6. Di Francesco D., John A. C. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 2004;64:1757–1765.
  7. Borer J. S., Fox K., Jaillon P. et al. Antianginal and antiischemic effects of ivabradine, an I (f) inhibitor, in stable angina: a randomized, double-blind, multicenter, placebo-controlled trial. Circulation 2003;107:817–823.
  8. Tardif J. C., Ford I., Tendera M. et al. for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529–2536.
  9. Ruzyllo W., Tendera M., Ford I., Fox K. M. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3‑month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67:393–405.
  10. Ho J. E., Bittner V., Demicco D. A. et al. Usefulness of heart rate at rest as a predictor ofmortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (data from the Treating to New Targets [TNT] trial. Am J Cardiol 2010;105:905–911.
  11. Swedberg K., Komajda M., Bohm M. et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? J Am Coll Cardiol 2012;59:1938–1945.
  12. Russian guidelines “Management of stable angina”. VNOK: Moscow, 2009. Russian (Российские рекомендации «Диагностика и лечение стабильной стенокардии». ВНОК: Москва, 2009).
  13. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949–3003.
  14. Fox K., Ford S. P. G., Tendera M. et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008;372:817–821.
  15. Ried L. D., Tueth M. J., Handberg E. et al. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosom Med 2005;67:398–406.
  16. Mc Alister F. A., Wiebe N., Ezekowitz J. A. et al. Meta-analysis: Beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784–794.
  17. Tendera M., Fox K., Ferrari R. et al. Inadequate Heart Rate Control Despite Widespread Use of Beta-Blockers in Outpatients With Stable CAD: Findings From the International Prospective CLARIFY Registry. Int J Cardiol 2014;176 (1):119–124.
  18. Tardif J. C., Ponikowski P., Kahan T. Study Investigators ASSOCIATE. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4‑month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540–548.
  19. Tardif J. C., Ponikowski P., KahanT. Investigators ASSOCIATE. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 2013;168:789–794.
  20. Werdan K., Ebelt H., Nuding S. et al. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol 2012;101:365–373.
  21. Werdan K., Perings S., Köster R. et al. Efficacy of If Inhibition with Ivabradine in Different Subpopulations with Stable Angina Pectoris. Cardiology 2016;135 (3):141–150.
  22. Fox K., Ford I., Steg P. G. et al., Investigators BEAUTIFUL. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807–816.
  23. Fox K., Ford I., Steg P. G. et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30:2337–2345.
  24. Swedberg K., Komajda M., Böhm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebocontrolled study. Lancet 2010;376:875–885.
  25. Ponikowski P., Voors A. A., Anker S. D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200.
  26. U. S. Food and Drug Administration. FDA approves Corlanor to treat heart failure [Web Page]. Available from: http://www.fda.gov/NewsEvents/Nwsroom /PressAnnouncements/ucm442978.htm
  27. Diaz A., Bourassa M. G., Guertin M. C., Tardif J. C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967–974.
  28. McAlister F. A., Wiebe N., Ezekowitz J. A. et al. Meta-analysis: betablocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784–794.
  29. Palatini P., Benetos A., Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs 2006;66 (2):133–144.
  30. Yusuf S., Wittes J., Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988;260 (14):2088–2093.
  31. Gould K. L., Lipscomb K. Effects of coronary stenosis on coronary flow reserve and resistance. Am J Cardiol 1974;34 (1):48–55.
  32. Bogren H. G., Buonocore M. H. Blood Flow Measurements in the Aorta and Major Arteries with MR Velocity Mapping. JMRI 1994;4:119–130.
  33. Miller D. D., Donohue T. J., Younis L. T. Correlation of pharmacological 99mTc-sestamibi myocardial perfusion imaging with poststenotic coronary flow reserve in patients with angiographically intermediate coronary artery stenoses. Circulation 1994;89 (5):2150–2160.
  34. Fearon W. F., Balsam L. B., Farouque H. M. Novel index forinvasively assessing the coronary microcirculation. Circulation 2003;107(25):3129–3132.
  35. Caiati C., Montaldo C., Zedda N. et al. New noninvasive method for coronary flow reserve assessment contrast-enhanced transthoracic second harmonic echo Doppler. Circulation 1999;99:771–778.
  36. Pijls N. H., Van Gelder B., Van der Voort P. et al. Fractional flow reserve: a useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation 1995;92:3183–3193.
  37. Mironov V. M., Merkulov E. V., Samko A. N. Assessment of fractional coronary blood flow reserve. Kardiologiia 2012;52 (8):66–71. Russian (Миронов В. М., Меркулов Е. В., Самко А. Н. Оценка фракционного резерва коронарного кровотока. Кардиология 2012;8:66–71.)
  38. Skalidis E. I., Hamilos M., Chlouverakis G. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Send to Atherosclerosis 2011;215 (1):160–165.
  39. Tagliamonte E., Cirillo T., Rigo F. et al. Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate. AdvTher 2015;32 (8):757–767.
  40. Tagliamonte E., Cirillo T., Rigo F. Rest and stress coronary diastolic perfusion time in patients with stable coronary artery disease treated with ivabradine or carvedilol: new insights into their mechanism of actions. Eur Heart J 2016;37 (suppl 1):3362.
  41. Levin D. C. Path ways and functional significance of the coronary collateral circulation. Circulation 1974;50:831–837.
  42. Cibulski A. A., Lehan P. H., Timmis H. H. Collateral regression following direct coronary revascularization in dogs. J Cardiovasc Surg 1973;14:390–394.
  43. Werner G. S., Emig U., Mutschke O. et al. Regression of collateral function after recanalization of chronic total coronary occlusions: a serial assessment by intracoronary pressure and doppler recordings. Circulation 2003;108:2877–2882.
  44. Gloekler S., Traupe T., Stoller M. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart 2014;100 (2):160–166.
  45. Bangalore S., Sawhney S., Messerli F. Relation of beta-blockerinduced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008;52:1482–1489.
  46. Law M. R., Morris J. K., Wald N. J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338: b1665.
  47. Williams B., Lacy P. S., Thom S. M. et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213–1225.
  48. Kobalava Z. D., Kotovskaya Y. V., Moiseev V. S. Arterial Hypertension: the keys to diagnosis and treatment. A guide for doctors. Moscow: GEOTAR Media 2009; 864. Russian (Кобалава Ж. Д., Котовская Ю. В., Моисеев В. С. Артериальная гипертония: ключи к диагностике и лечению. Руководство для врачей. М: ГЭОТАР-Медиа 2009; 864).
  49. Dillinger J. G., Maher V., Vitale C. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease. Hypertension 2015;66 (6):1138–1144. doi: 10.1161/HYPERTENSIONAHA.115.06091. Epub 2015 Sep 21.
  50. Shavarov A. A., Kiyakbaev G. K., Kobalava Z. D. Central blood pressure and arterial stiffness in patients with stable angina and arterial hypertension without left ventricle systolic dysfunction: effects of atenolol and ivabradine. Serdechnaya Nedostatochnost 2015; 16 (3):179–186. Russian (Шаваров А. А., Киякбаев Г. К., Кобалава Ж. Д. Центральное давление и артериальная жесткость у больных стабильной стенокардией и артериальной гипертонией без систолической дисфункции левого желудочка: эффекты атенолола и ивабрадина. Журнал Сердечная Недостаточность 2015;16 (3):179–186.)
  51. Burns J., Mary D. A. S. G., Mackintosh A. F. et al. Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive. Hypertension 2004;44:454–458.
  52. Kirichenko L. L., Golosova A. N., Gatsura S. V. et al. Comparison of endothelial function in patients with Stage I–II arterial hypertension and stable angina, receiving various bradycardic agents and perindopril. Cardiovascular Therapy and Prevention 2009;7:25–31. Russian (Кириченко Л. Л., Голосова А. Н., Гацура С. В. и др. Сравнительная оценка состояния эндотелиальной функции у больных артериальной гипертонией I–II степени и стабильной стенокардией при применении различных брадикардитических препаратов в сочетании с периндоприлом. Кардиоваскулярная терапия и профилактика 2009;7:25–31).
  53. Golosova A. N., Kirichenko L. L., Gatsura S. V. Comparative study of perindopril/ivabradine and perindopril/metoprolol combinations effect on microcirculatory blood flow in hypertensive patients with coronary heart disese. 20TH European Meeting on Hypertension. Oslo June 18–23, 2010. Abstract book 2010; p 70
  54. Cappato R., Castelvecchio S., Ricci C. et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol 2012;60 (15):1323–1329.
  55. Krahn A. D., Yee R., Klein G. J., Morillo C. Inappropriate sinus tachycardia: evaluation and therapy. J Cardiovasc Electrophysiol 1995;6: 1124–1128.
  56. Shen W. K. How to manage patients with inappropriate sinus tachycardia. Heart Rhythm 2005;1015–1019.
  57. Diagnosis and Management of Cardiac Arrhythmias. National Clinical Guidelines. Kardiologicheskij Vestnik 2014;9 (2):3–31. Russian (Российские клинические рекомендации по диагностике и лечению нарушений ритма сердца и проводимости. Кардиологический вестник 2014;9 (2):3–31).
  58. Shen W. K., Low P. A., Jahangir A. et al. Is sinus node modification appropriate for inappropriate sinus tachycardia with features of postural orthostatic tachycardia syndrome? Pacing Clin Electrophysiol 2001;24:217–230.
  59. Morillo C. A., Klein G. J., Thakur R. K. et al. Mechanisms of inappropriate sinus tachycardia: role of sympathovagal imbalance. Circulation 1994;90:873–877.
  60. Chiale P. A., Garro H. A., Schmidberg J. et al. Inappropriate sinus tachycardia may be related to an immunologic disorder involving adrenergic receptors. Heart Rhythm 2006;3:1182–1186.
Голосова А. Н., Гацура С. В., Ульянова Е. А., Карамышева Е. И., Дворянчикова Ж. Ю. Ивабрадин в современной фармакотерапии сердечно-сосудистых заболеваний – реалии и перспективы. Кардиология. 2018;58(2):68–76.

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En